-       Report 
- December 2024
-  44 Pages 
- Global 
   From       €313EUR$350USD£275GBP 
          -       Report 
- December 2024
-  38 Pages 
- Turkey 
   From       €313EUR$350USD£275GBP 
          -       Report 
- December 2024
-  42 Pages 
- United Kingdom 
   From       €313EUR$350USD£275GBP 
          -       Report 
- December 2024
-  40 Pages 
- Spain 
   From       €313EUR$350USD£275GBP 
          -       Report 
- December 2024
-  38 Pages 
- Netherlands 
   From       €313EUR$350USD£275GBP 
           -       Report 
- December 2024
-  36 Pages 
- Italy 
   From       €313EUR$350USD£275GBP 
          -       Report 
- December 2024
-  42 Pages 
- Germany 
   From       €313EUR$350USD£275GBP 
          -       Report 
- December 2024
-  41 Pages 
- France 
   From       €313EUR$350USD£275GBP 
          -       Report 
- December 2024
-  36 Pages 
- Russia 
   From       €313EUR$350USD£275GBP 
          -       Report 
- December 2024
-  43 Pages 
- Australia 
   From       €313EUR$350USD£275GBP 
          -       Report 
- December 2024
-  39 Pages 
- South Korea 
   From       €313EUR$350USD£275GBP 
          -       Report 
- December 2024
-  35 Pages 
- Singapore 
   From       €313EUR$350USD£275GBP 
          -       Report 
- December 2024
-  44 Pages 
- Japan 
   From       €313EUR$350USD£275GBP 
          -       Report 
- July 2023
-  47 Pages 
- United Kingdom 
   From       €313EUR$350USD£275GBP 
          -       Report 
- July 2023
-  41 Pages 
- Global 
   From       €313EUR$350USD£275GBP 
          -       Report 
- July 2023
-  47 Pages 
- China 
   From       €313EUR$350USD£275GBP 
          -       Report 
- July 2023
-  44 Pages 
- North America 
   From       €313EUR$350USD£275GBP 
          -       Report 
- July 2023
-  41 Pages 
- Indonesia 
   From       €313EUR$350USD£275GBP 
          -       Report 
- July 2023
-  45 Pages 
- Australia 
   From       €313EUR$350USD£275GBP 
          -       Report 
- July 2023
-  47 Pages 
- Netherlands 
   From       €313EUR$350USD£275GBP 
       
      Branded generics are generic drugs that are marketed under a brand name. They are typically manufactured by a generic drug company, but are sold under a brand name owned by a pharmaceutical company. Branded generics are typically sold at a higher price than generic drugs, but are still much cheaper than the original brand-name drug. They are often used to increase the market share of a generic drug company, as well as to increase the visibility of a generic drug in the marketplace.
Branded generics    are becoming increasingly popular in the pharmaceutical industry, as they offer a cost-effective alternative to brand-name drugs. They are also used to increase the market share of generic drug companies, as well as to increase the visibility of generic drugs in the marketplace.
Some companies in the branded generics market include Teva Pharmaceuticals, Mylan, Sandoz, and Dr. Reddy's Laboratories. Show Less   Read more